Selected articles
Articles for label Štork Martin are displayed.. Show all articles
Monoclonal antibodies in relapsed or refractory multiple myeloma treatment
02/2018 MUDr. Martin Štork
Nowadays the multiple myeloma treatment with monoclonal antibodies goes through a dynamic development. Within the clinical trials there are available new three monoclonal antibodies - daratumumab, elotuzumab and isatuxiamb. The efficacy of anti-CD38 monoclonal antibody daratumumab is already known from monotherapy in heavily pretreated patients. Daratumumab monotherapy in heavily-pretreated patients shows 30% overall response rate and response persisted for more than half a year. Combination of daratumumab and imunomodulatory drugs shows more than 90% response rate and significant extension of progression-free survival versus standard care in relapsed patients. Elotuzumab in combination with lenalidomide and dexamethasone, achieved in 79% of patient's partial remission and better treatment response and median PFS was 19.4 months. Isatuximab is a new anti-CD38 monoclonal antibody. In phase Ib or II clinical trials Isatuximab achieved very promising results in heavily pre-treated patients. Monoclonal antibodies are highly effective and minimally toxic in the multiple myeloma treatment. They are an ideal complement to the standard treatment protocols. This review summarizes present clinical data about monoclonal antibodies treatment in relapsed multiple myeloma patients.
ENTIRE ARTICLE
Nowadays the multiple myeloma treatment with monoclonal antibodies goes through a dynamic development. Within the clinical trials there are available new three monoclonal antibodies - daratumumab, elotuzumab and isatuxiamb. The efficacy of anti-CD38 monoclonal antibody daratumumab is already known from monotherapy in heavily pretreated patients. Daratumumab monotherapy in heavily-pretreated patients shows 30% overall response rate and response persisted for more than half a year. Combination of daratumumab and imunomodulatory drugs shows more than 90% response rate and significant extension of progression-free survival versus standard care in relapsed patients. Elotuzumab in combination with lenalidomide and dexamethasone, achieved in 79% of patient's partial remission and better treatment response and median PFS was 19.4 months. Isatuximab is a new anti-CD38 monoclonal antibody. In phase Ib or II clinical trials Isatuximab achieved very promising results in heavily pre-treated patients. Monoclonal antibodies are highly effective and minimally toxic in the multiple myeloma treatment. They are an ideal complement to the standard treatment protocols. This review summarizes present clinical data about monoclonal antibodies treatment in relapsed multiple myeloma patients.